|
October 25, 2000
Canaccord Capital Corporation initiates coverage of Neurochem
Neurochem Inc. (TSX : NRM) today announced that Canaccord Capital Corporation analyst, Mr.
Wayne Schnarr, has initiated coverage of the Company. "Canaccord in now the second
firm to initiate coverage on Neurochem this fall," said Dr. Louis R. Lamontagne,
President and CEO. "Interest by the financial community in Neurochem since our
listing on the TSX is extremely encouraging," he added.
Neurochem is an industry leader in the development of a novel, proprietary series of
compounds that inhibit the formation, deposit and toxic effects of amyloid fibrils on
cells within the body. Neurochem's research team has been working with international
amyloid experts on the development of therapeutic cures to amyloid-related diseases,
including Alzheimer's disease, Secondary Amyloidosis , Diabetes Type II and Hemorrhagic
Stroke (due to Cerebral Amyloid Angiopathy). Neurochem has advanced three drug candidates to
clinical trials: Alzhemed™, for the treatment of Alzheimer's disease,
Fibrillex™, for Secondary Amyloidosis, and Cerebril™, for
Hemorrhagic Stroke. At present, the Company employs over 50 people and is located in
Saint-Laurent, Canada (www.neurochem.com).
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
|
